Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study
European Journal of Cancer · 2026-11 · 248 · 117450
DOI: 10.1016/j.ejca.2026.117450 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Celine Khouri und 24 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy, Département de l'oncologie de l'enfant et de l'adolescent, Villejuif, Paris Kids Cancer. French Cancer Society (SFCE), France. Hauptthemen laut MEDLINE: Pyrimidinones, Pyridones, Proto-Oncogene Proteins B-raf, Glioma. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: MEK inhibition has demonstrated activity in pediatric low-grade gliomas (pLGGs) driven by BRAF rearrangements, but data on trametinib remain limited, regarding efficacy, short and long-term toxicities. METHODS: We conducted a retrospective multicenter study of patients with BRAF-rearranged non NF1 pLGGs receiving trametinib across three French pediatric oncology centers. Plasma concentrations were monitored. RESULTS: Between 2015 and 2023, 46 patients had a median age of 8.7 years (range 1.2-18.6). Trametinib achieved a radiological disease control rate of 78% (36/46), including 65% partial or minor responses and 13% stable disease, with activity even in heavily pretreated (up to 6 lines) and chemotherapy-refractory tumors. Clinical improvement occurred in 72% of patients. Median treatment duration was 14.2 months (range, 1.0-55.1). Among 35 patients who discontinued treatment, 37% remained treatment-free after a median follow-up of 16.1 months (4.3-44.2). Grade 3 treatment-related adverse events occurred in one-third of patients. Common toxicities included cutaneous events (69%), paronychia (64%), gastrointestinal symptoms (51%), elevated creatine kinase (54%) and transaminases (31%). Ophthalmologic (16%) toxicities and epistaxis (17%) of which 35% were grade 2 and required intervention, were observed. Body mass index Z-score increased during treatment but was clinically significant (≥1 SD) and related to trametinib in only 17% of patients. Pharmacokinetics showed high interpatient variability, with no correlation between plasma concentrations and efficacy or toxicity. CONCLUSION: Trametinib demonstrates sustained activity in BRAF-rearranged pLGGs, including in heavily pretreated patients. This study represents the largest reported cohort of BRAF-rearranged pLGGs, expanding prior evidence and supporting a class effect of MEK inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gustave Roussy, Département de l'oncologie de l'enfant et de l'adolescent, Villejuif, Paris Kids Cancer. French Cancer Society (SFCE), France.
- Institute of Pediatric Hematology and Oncology (iHOPe), Centre SouthRock, Lyon, France.
- Curie Institute, SiREDO Pediatric Cancer Center and Curie Institute SIRIC, Paris, France.
- Department of Pharmacology, Gustave Roussy, Villejuif, France.
- Department of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, Paris, France.
- Pediatric Neurosurgery Department, AP-HP, Hôpital Universitaire Necker, Enfants Malades, Paris, France.
Zitieren
APA
Khouri, C., Bibollet, A., Bouchoucha, Y., Combarel, D., Delahousse, J., Aerts, I., Bourdeaut, F., Tauziede-Espariat, A., Metais, A., Varlet, P., Beccaria, K., Blauwblomme, T., Guida, L., Benichi, S., Kariyawasam, D., Dangouloff-Ros, V., Boddaert, N., Sellami, N., Dufour, C., …, & Abbou, S. (2026). Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study. European Journal of Cancer, 248, 117450. https://doi.org/10.1016/j.ejca.2026.117450
Vancouver
Khouri C, Bibollet A, Bouchoucha Y, Combarel D, Delahousse J, Aerts I, et al. Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study. European Journal of Cancer. 2026;248:117450. doi:10.1016/j.ejca.2026.117450
BibTeX
@article{Khouri2026,
author = {Khouri, Celine and Bibollet, Amandine and Bouchoucha, Yassine and Combarel, David and Delahousse, Julia and Aerts, Isabelle and Bourdeaut, Franck and Tauziede-Espariat, Arnault and Metais, Alice and Varlet, Pascale and Beccaria, Kevin and Blauwblomme, Thomas and Guida, Lelio and Benichi, Sandro and Kariyawasam, Dulanjalee and Dangouloff-Ros, Volodia and Boddaert, Nathalie and Sellami, Noura and Dufour, Christelle and Simbozel, Marie and Guerrini-Rousseau, Lea and Geoerger, Birgit and Grill, Jacques and Leblond, Pierre and Abbou, Samuel},
title = {Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117450},
doi = {10.1016/j.ejca.2026.117450}
}
EUVIMED